Department of Orthopedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Peking University, 31 Xinjiekou East Street, Xicheng District, Beijing 100035, China.
J Bone Joint Surg Am. 2012 Mar 7;94(5):461-7. doi: 10.2106/JBJS.J.01922.
There are no recent reports of giant cell tumors of bone in a large series of Chinese people. The present study was designed to review the epidemiological characteristics and outcomes of surgical management in a large series of Chinese patients with giant cell tumor of an extremity, treated at a single institution.
The records and images of 621 patients in whom a benign giant cell tumor in an extremity was treated between 1989 and 2009 were reviewed retrospectively. There were 359 male and 262 female patients. The mean age at diagnosis was 31.4 years (range, eleven to seventy-one years). Sixty-six percent of the giant cell tumors were localized around the knee. Surgical treatments primarily included curettage, extensive curettage, and resection. The median duration of follow-up was forty-nine months (range, eighteen to 256 months).
Giant cell tumor accounted for 13.7% of all primary bone tumors treated at our institution. Multivariate Cox regression analysis indicated that the only variable that contributed to recurrence-free survival was the type of surgical treatment. The local recurrence rate after extensive curettage was 8.6%, which was significantly lower than the 56.1% recurrence rate after curettage alone. Bone-grafting did not affect local tumor control after extensive curettage; the local recurrence rate was 11.1% if bone graft was used. Recurrent giant cell tumor can be treated by further curettage or resection, with acceptable re-recurrence rates of 6.7% and 9.3% respectively. The Musculoskeletal Tumor Society Score for patients treated with extensive curettage was 92.6%, which was significantly higher than that for patients treated with resection. Twenty-one (3.4%) of the 621 patients developed benign pulmonary metastasis, with a favorable outcome, and three patients presented with multifocal giant cell tumors.
The incidence of giant cell tumor in the Chinese population may be higher than that in Western countries, and it has a male predilection. The results of the present study suggest that extensive curettage provides favorable local control and satisfactory functional outcomes.
目前尚未有关于中国人群中发生大量骨巨细胞瘤的报道。本研究旨在回顾单中心收治的 621 例肢体骨巨细胞瘤患者的流行病学特征和外科治疗结果。
回顾性分析 1989 年至 2009 年期间收治的 621 例肢体良性骨巨细胞瘤患者的病历资料和影像学资料。其中男 359 例,女 262 例。患者的平均年龄为 31.4 岁(11 岁至 71 岁)。66%的骨巨细胞瘤位于膝关节周围。外科治疗主要包括刮除术、广泛刮除术和切除术。中位随访时间为 49 个月(18 至 256 个月)。
骨巨细胞瘤占我院收治的所有原发性骨肿瘤的 13.7%。多变量 Cox 回归分析表明,唯一与无复发生存相关的变量是手术方式。广泛刮除术后局部复发率为 8.6%,显著低于单纯刮除术的 56.1%。广泛刮除术后植骨并不影响局部肿瘤控制;植骨后局部复发率为 11.1%。复发性骨巨细胞瘤可进一步采用刮除术或切除术治疗,再次复发率分别为 6.7%和 9.3%。广泛刮除术患者的肌肉骨骼肿瘤学会评分(Musculoskeletal Tumor Society Score)为 92.6%,显著高于切除术患者。621 例患者中,21 例(3.4%)发生良性肺转移,预后良好,3 例患者表现为多灶性骨巨细胞瘤。
中国人群中骨巨细胞瘤的发病率可能高于西方国家,且存在男性发病倾向。本研究结果表明,广泛刮除术可提供良好的局部控制和满意的功能结局。